EUVIMEDEUVIMED entdecken
VergleichsstudieEvaluationsstudie

Comparison of CLSI and EUCAST broth microdilution reference methods for antifungal susceptibility testing of Candida (Candidozyma) auris using a representative international panel of isolates: a single-centre study

Maria Siopi iD, Sevasti Leventaki, Ioannis Pachoulis, Bram Spruijtenburg, Eelco F J Meijer, Jacques F Meis iD, Spyros Pournaras, Athanasios Tsakris, Georgia Vrioni, Joseph Meletiadis iD

Journal of Antimicrobial Chemotherapy · 06.10.2026 · 81 (11)

DOI: 10.1093/jac/dkag361 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 02.11.2026. Verfasst von Maria Siopi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Microbiology Laboratory, 'Attikon' University General Hospital, Medical School, National and Kapodistrian University of Athens, Rimini 1, Ha…. Hauptthemen laut MEDLINE: Antifungal Agents, Candida auris, Candida. Die Arbeit nennt 25 Literaturangaben. Gefördert von: Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The two reference broth microdilution antifungal susceptibility methods, developed by the CLSI and EUCAST, were compared qualitatively and quantitatively using an international collection of 107 Candida (Candidozyma) auris clinical isolates including azole- and echinocandin-resistant isolates.

Methods

Inter-method agreement within ±1 twofold dilution was assessed for all drugs. Categorical agreement (CA) was evaluated for amphotericin B, anidulafungin and micafungin using the CDC tentative resistance breakpoints and the recently proposed EUCAST clinical breakpoints for C. auris.

Results

CLSI-EUCAST agreement was moderate to strong for itraconazole (44%), posaconazole (52%), isavuconazole (70%), voriconazole (72%), micafungin (81%), caspofungin (86%), and anidulafungin (87%), and excellent for 5-flucytosine (93%) and amphotericin B (100%). All isolates were categorized as non-resistant to amphotericin B by both methods (100% CA). CA was 92% for anidulafungin and 94% for micafungin, with 8% and 6% major errors, respectively, with CDC breakpoints classifying 33%–44% of FKS1 mutants as non-resistant. While all FKS1 mutants exceeded EUCAST ECOFF values, 11% and 28% fell at or below the corresponding CLSI ECV values for micafungin (0.5 mg/L) and anidulafungin (1 mg/L), respectively, with MICs 0.5–1 mg/L. For caspofungin, all non-wild-type isolates harboured FKS1 mutations, but 6% of isolates without FKS1 mutations had MICs 1 dilution higher than CLSI ECV for caspofungin (0.5 mg/L).

Conclusions

Despite high overall concordance between CLSI and EUCAST MICs, discrepancies in wild-type classification among FKS1 mutants highlight the need for harmonized interpretive criteria. Azole MIC variability further underscores the need for standardized breakpoints.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsCandida aurisCandidaMicrobial Sensitivity TestsHumansDrug Resistance, FungalEchinocandinsCandidiasis

Substanzen

Antifungal AgentsEchinocandins

Autor:innen und Institutionen

  • Clinical Microbiology Laboratory, 'Attikon' University General Hospital, Medical School, National and Kapodistrian University of Athens, Rimini 1, Haidari, 124 62 Athens, Greece.
  • Molecular Microbiology and Immunology Laboratory, Department of Biomedical Sciences, University of West Attica, Athens, Greece.
  • Department of Medical Microbiology and Ιmmunology, Canisius-Wilhelmina Hospital (CWZ)/Dicoon, Nijmegen, The Netherlands.
  • Radboudumc-CWZ Center of Expertise for Mycology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Excellence Center for Medical Mycology (ECMM), University of Cologne, Cologne, Germany.
  • Department of Microbiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

ORCID-Profile: Maria Siopi, Jacques F Meis, Joseph Meletiadis

Förderung

  • Gilead Sciences

Zitieren

APA

Siopi, M., Leventaki, S., Pachoulis, I., Spruijtenburg, B., Meijer, E. F. J., Meis, J. F., Pournaras, S., Tsakris, A., Vrioni, G., & Meletiadis, J. (2026). Comparison of CLSI and EUCAST broth microdilution reference methods for antifungal susceptibility testing of Candida (Candidozyma) auris using a representative international panel of isolates: a single-centre study. Journal of Antimicrobial Chemotherapy, 81(11). https://doi.org/10.1093/jac/dkag361

Vancouver

Siopi M, Leventaki S, Pachoulis I, Spruijtenburg B, Meijer EFJ, Meis JF, et al. Comparison of CLSI and EUCAST broth microdilution reference methods for antifungal susceptibility testing of Candida (Candidozyma) auris using a representative international panel of isolates: a single-centre study. Journal of Antimicrobial Chemotherapy. 2026;81(11). doi:10.1093/jac/dkag361

BibTeX
@article{Siopi2026,
  author = {Siopi, Maria and Leventaki, Sevasti and Pachoulis, Ioannis and Spruijtenburg, Bram and Meijer, Eelco F J and Meis, Jacques F and Pournaras, Spyros and Tsakris, Athanasios and Vrioni, Georgia and Meletiadis, Joseph},
  title = {Comparison of CLSI and EUCAST broth microdilution reference methods for antifungal susceptibility testing of Candida (Candidozyma) auris using a representative international panel of isolates: a single-centre study},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  volume = {81},
  number = {11},
  doi = {10.1093/jac/dkag361}
}
Kostenlos starten →